打开APP

Idenix治疗丙肝新药被FDA驳回

  1. FDA
  2. Idenix
  3. 丙肝新药

来源:生物谷 2013-06-25 08:32

2013年6月23日讯 /生物谷BIOON/ --Idenix医药公司目前陷入了新的困境。FDA日前对公司研发的新药IDX20963提出了质疑。IDX20963是Idenix公司研发的一种口服型丙肝药物。该消息已经披露,公司股价出现下滑。这次质疑使公司对IDX20963的人体临床试验被迫延迟。

2013年6月23日讯 /生物谷BIOON/ --Idenix医药公司目前陷入了新的困境。FDA日前对公司研发的新药IDX20963提出了质疑。IDX20963是Idenix公司研发的一种口服型丙肝药物。该消息已经披露,公司股价出现下滑。这次质疑使公司对IDX20963的人体临床试验被迫延迟。

据估计,全球治疗这种疾病的口服药物市场总份额约为200亿美元,这次挫折可能会延迟Idenix分润这一巨大市场的时间。(生物谷Bioon.com)

详细英文报道:

Idenix Pharmaceuticals ($IDIX) has encountered another big roadblock in the race to develop oral drugs for hepatitis C virus. The FDA has hit the biotech group with a request for more preclinical data on IDX20963, which is Idenix's lead drug in the closely watched class of uridine nucleotide prodrugs, sometimes called "nucs" for short.

The company's shares tumbled 38% in after-hours trading--dropping to $3.18--as analysts started to discount the chances of success for this program, a bitter setback for Idenix as it struggles to get back on track.

The request delays the start of human testing of the compound and follows previous troubles with the FDA over Indenix's experimental hep C drugs. In February the company ditched development of two nucleotide polymerase inhibitors known as IDX184 and IDX19368, opting to ice the programs after the FDA placed them on hold because of dire safety problems with a similar compound from Bristol-Myers Squibb ($BMY) called BMS-986094.

Bristol's compound triggered heart failure in one patient and led to serious side effects in others, prompting the company to write off most of the $2.5 billion it spent to acquire the program from Inhibitex less than a year before the problems occurred.

Idenix has stayed in the hep C race with a midstage study of an NS5A inhibitor called IDX719. Still, nucs have proven to provide potent attacks on the liver-damaging virus without requiring injections of interferon, which causes flu-like side effects. Gilead Sciences ($GILD) could have its lead nuc drug called sofosbuvir on the U.S. market by next year, giving the company the first interferon-free treatment for hep C.

The all-oral treatments for the disease are expected to surpass $20 billion in annual sales, but it could take Idenix much longer to grab a piece of the action.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->